ClinicalTrials.gg
CompletedNCT00363948Updated Jun 13, 2012

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Placebo and Sitagliptin phosphate in Type 2 Diabetes Mellitus, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 8 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2012-06-13.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
75th of 197
188 · median 102
Started
2006
with 12 others
Phase 3
74 of 198
none open now
Registered
14th of 198
by date
Lead sponsor
5 of 198
Ono Pharmaceutical Co. Ltd

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 75th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2006, is one of 74 in phase 3, and was the 14th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and metformin as monotherapy

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • MK-0431
  • ONO-5435
  • Type 2 diabetes mellitus
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes mellitus on diet/exercise therapy and metformin as monotherapy

Exclusion criteria

Exclusion Criteria:

  • Patients with type 1 diabetes mellitus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Placebo comparator
    P

    Drug: Placebo

  • Experimental
    E

    Drug: Sitagliptin phosphate

Interventions

  • DrugPlacebo

    Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD

06

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: 12 weeks

  2. safety

    Time frame: 52 weeks

  3. tolerability

    Time frame: 52 weeks

Secondary outcomes

  1. Plasma glucose

    Time frame: 12 weeks

07

Study locations

8 sites
  • Chubu Region
    Chubu, Japan
  • Chugoku Region
    Chugoku, Japan
  • Hokkaido Region
    Hokkaido, Japan
  • Hokuriku Region
    Hokuriku, Japan
  • Kanto Region
    Kanto, Japan
  • Kinki Region
    Kinki, Japan
  • Kyushu Region
    Kyushu, Japan
  • Tohoku Region
    Tohoku, Japan
08

References and documents

Publications

  • Kadowaki T, Tajima N, Odawara M, Nishii M, Taniguchi T, Ferreira JC. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Investig. 2013 Mar 18;4(2):174-81. doi: 10.1111/jdi.12001. Epub 2012 Oct 22. PubMed 24843649 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006 and a primary completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2006
First posted
Aug 15, 2006
Start
Aug 2006
Primary completionActual
Feb 2008
Last update
Jun 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00363948
Responsible party
Sponsor
First posted
Aug 15, 2006
Start date
Aug 2006
Primary completion
Feb 2008
Last update
Jun 13, 2012

Study contacts

Mikio Nishii
study director · Ono Pharmaceutical Co. Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion